Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × idecabtagene vicleucel × Clear all

Phase

Status

Completed 2 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 3 Recurrence 1

Interventions

Cyclophosphamide 18 Dexamethasone 17 fludarabine 11 pomalidomide 8 carfilzomib 7 Rituximab 7 pembrolizumab 6 fludarabine phosphate 6 daratumumab 6 Lenalidomide 6 Calcium Dobesilate 6 venetoclax 5 Gemcitabine 5 Cisplatin 5 Bortezomib 5 Nivolumab 4 Etoposide 4 isatuximab 3 elotuzumab 3 Vincristine 3 Prednisone 3 Ipilimumab 3 Injections 3 Doxorubicin 3 Carboplatin 3 tisagenlecleucel 2 ruxolitinib 2 obinutuzumab 2 dexamethasone 21-phosphate 2 cemiplimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03651128 2022-12-15

KarMMa-3

Celgene

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡